Portfolio company
T-Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
3T Biosciences
The company develops T-cell receptor therapeutics and target identification technologies for oncology patients to treat solid tumours.
Immunocore
This biotechnology company develops T cell receptor immunotherapies to treat patients with cancer, infectious diseases and autoimmune conditions.
Candid Therapeutics
This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
ATB Therapeutics
The company develops engineered antibody therapies for patients with cancer and autoimmune diseases using a proprietary bioengineering platform.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
Ypsilon Therapeutics
The company develops T-cell receptor mimic antibodies and bispecific T-cell engagers to treat patients with solid tumours, such as triple-negative breast and lung cancer.
Reverb Therapeutics
This biotechnology company develops bispecific antibody therapies that redirect the body's natural cytokines to treat patients with cancer and autoimmune diseases.